We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
West is proud to participate in Pharmapack’s upcoming symposium focused on Primary Packaging and Drug Delivery Trends for Injectables. The meeting, that will include presentations from leading suppliers and partners to the pharmaceutical industry, will be held on April 23 in New York at the W- Times Square.
During the session, the group will discuss new trends and developments in the field of injectable drugs and the primary packaging and delivery systems for these drugs. West’s Tibor Hlobik, Global Director, Marketing for PFS Technologies, will address developing a comprehensive prefilled drug delivery strategy that includes components intended to minimize risks.
As commercializing products has become more challenging, component design and material selection during development must take into account the drug stability during storage, robustness of the container closure system and intended user requirements to ensure safety and effectiveness of the medicine. In his talk, Tibor will review component selection strategies being applied by leading companies for multiple drug delivery formats to provide the highest standards in quality and support the needs of combination products.
West is participating is this symposium workshop series in Europe and Asia in addition to the April event in the United States. In addition to presenting, West is a sponsor and will exhibit during the meetings.
To learn more about West’s syringe components, visit our webpage.
Allergy to natural rubber latex was first documented in the late 1970s. The condition now commonly known as “Latex allergy” is caused by the proteins produced from the rubber tree (Hevea brasiliensis) that are still present in the products manufactured from natural rubber latex. This allergy is not only caused by the proteins, but also by the chemicals and/or residues thereof.
<span>Understanding extractables and leachables (E&L) is an essential element of determining the suitability of a packaging or delivery system for a drug product. Recently, PDA presented an <a href="https://www.youtube.com/watch?v=mol_X2zQeig">interview with Dan Mellon, Ph.D., Pharmacology Toxicology Supervisor at CDER’s Office of New Drugs</a>, discussing FDA’s approach to evaluating E&L information </span>
In today’s increasingly complex drug delivery and device development landscape, a reliable contract manufacturing partner can become a distinct competitive advantage for pharmaceutical and device companies. West brings together the right combination of insights and infrastructure to help our customers reduce costs, mitigate risk and accelerate path to market.
Modern biopharmaceutical drug molecules are often complex protein structures that need to maintain the molecular structure in order to convey full potency. With biologics, any alteration of the 3-D structure could lead to loss of activity or even to immunogenic reactions in the patient. Proteins can be disrupted by interactions with the container closure or with leachables. West FluroTec® lamination was chosen for NovaPure® plungers to reduce the interaction between the drug product and elastomer material. This includes less adsorption to the plunger surface as well as reduction of the leachables profile of the plunger, helping to maintain the stability of complex molecules.
Prefillable syringes have become an increasingly important option in the packaging and delivery of injectable drug products. The prefillable syringe serves two major purposes for the administration of a drug. The first is as primary packaging by assuring that there is no adverse effect on the identity, strength, quality, purity or potency of the drug over its shelf life. Second, a prefillable syringe is a delivery system designed to administer the appropriate amount of the drug to the patient reliably
English
Chinese
